Given that the expression levels of both PAK1 and BCAT1 were up‐regulated in ibrutinib‐resistant cells, we performed GSEA to explore the enriched pathways in CLL. The gene discussed is PAK1; the disease is B-cell chronic lymphocytic leukemia.